Your browser doesn't support javascript.
loading
The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists.
Merks, Piotr; Swieczkowski, Damian; Byliniak, Michal; Drozd, Mariola; Krupa, Katarzyna; Jaguszewski, Milosz; Brindley, David A; Naughton, Bernard D.
Afiliação
  • Merks P; Department of Pharmaceutical Technology, Faculty of Pharmacy, Ludwig Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Torun, Poland.
  • Swieczkowski D; Department of Pharmaceutical Technology, Faculty of Pharmacy, Ludwig Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Torun, Poland.
  • Byliniak M; First Department of Cardiology, Medical University of Gdansk, Gdansk, Poland.
  • Drozd M; Regional Pharmaceutical Chamber, Warsaw, Poland.
  • Krupa K; Department of Applied Pharmacy, Medical University of Lublin, Lublin, Poland.
  • Jaguszewski M; Tokarski-Olszewski Law Firm, Warsaw, Poland.
  • Brindley DA; First Department of Cardiology, Medical University of Gdansk, Gdansk, Poland.
  • Naughton BD; Said Business School, University of Oxford, Oxford, UK.
Eur J Hosp Pharm ; 25(1): 10-15, 2018 Jan.
Article em En | MEDLINE | ID: mdl-29445453
ABSTRACT
By February 2019, the Polish pharmaceutical industry, community and hospital pharmacies, wholesalers and parallel traders must all comply with the EU-wide Falsified Medicines Directive (FMD) legislation (2011/62/EU), to ensure that no medicinal product is dispensed to a patient without proper tracking and authentication. Here we describe how Poland is complying with the new EU regulations, the actions that have been taken to incorporate the FMD into Polish Pharmaceutical Law and whether or not these actions are sufficient. We found that Poland is only partially compliant with the FMD and further actions need to be undertaken to fully meet the Delegated Act (DA) requirements. Moreover, there is lack of awareness in Poland about the prevalence of falsified medication and the time scale required for implementation of the DA. Based on our findings, we suggest that a public awareness campaign should be started to raise awareness of the increased number of falsified medicines in the legal supply chain and that drug authorisation systems are implemented by Polish pharmacies to support the FMD.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article